The findings revealed that treatment with hemagglutinine resulted in downregulation of CD34, Ki67, EGFR, Bcl-2, and VEGF expressions in tumor tissues while up-regulating the pro-apoptotic protein Bax expression. The gene discussed is BCL2; the disease is neoplasm.